1215767-89-7

Usage

Uses

Used in Pharmaceutical Industry:
1,3-Dichloro-5-bromoisoquinoline is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique halogenated structure allows for the creation of a wide range of organic compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 1,3-dichloro-5-bromoisoquinoline serves as a crucial building block for the synthesis of various agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control and crop protection.
Used in Organic Synthesis:
1,3-Dichloro-5-bromoisoquinoline is utilized as a versatile building block in organic synthesis, enabling the production of a diverse array of organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of complex organic molecules for various applications.

Upstream product

• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 
• 7742-73-6 1,3-dichloroisoquinoline 

Downstream Products

• 1029720-67-9 5-bromo-3-chloroisoquinoline 
• 1362689-90-4 5-bromo-3-((4-fluorophenyl)thio)isoquinolin-1-ol 

Relevant academic research and scientific papers

The Dimeric Form of 1,3-Diaminoisoquinoline Derivative Rescued the Mis-splicing of Atp2a1 and Clcn1 Genes in Myotonic Dystrophy Type 1 Mouse Model

Expanded CUG repeat RNA in the dystrophia myotonia protein kinase (DMPK) gene causes myotonic dystrophy type 1 (DM1) and sequesters RNA processing proteins, such as the splicing factor muscleblind-like 1 protein (MBNL1). Sequestration of splicing factors results in the mis-splicing of some pre-mRNAs. Small molecules that rescue the mis-splicing in the DM1 cells have drawn attention as potential drugs to treat DM1. Herein we report a new molecule JM642 consisted of two 1,3-diaminoisoquinoline chromophores having an auxiliary aromatic unit at the C5 position. JM642 alternates the splicing pattern of the pre-mRNA of the Ldb3 gene in the DM1 cell model and Clcn1 and Atp2a1 genes in the DM1 mouse model. In vitro binding analysis by surface plasmon resonance (SPR) assay to the r(CUG) repeat and disruption of ribonuclear foci in the DM1 cell model suggested the binding of JM642 to the expanded r(CUG) repeat in vivo, eventually rescue the mis-splicing.

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF HIV

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds a

GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.